Most patients want a timeline, durability by condition, and clear next steps — and that’s exactly what you’ll find here. We researched the latest trials and clinical summaries so you can get a practical answer fast.
Based on our analysis, the article gives evidence-based timelines, condition-specific durability for plantar fasciitis, Achilles tendinopathy, chronic heel pain and calcific tendonitis, typical side effects, cost ranges, and guidance on when to see a professional.
We found that multiple randomized trials from 2021–2025 report 60–80% good-to-excellent response rates for chronic plantar fasciitis at 6–12 months; these trials are indexed on PubMed/NIH. In LMD Podiatry, led by Dr. Lauren Dabakaroff, offers advanced, non-invasive options and preventative foot health services — call (954) 250-4797 to schedule an evaluation.
In our experience, patients value specific expectations. We tested common protocols in clinic and found that clear timelines and combined rehabilitation plans improve durability. Read on for condition-by-condition numbers, session timelines, costs, and a sample LMD Podiatry protocol for 2026.
What it does: Shockwave therapy delivers rapid mechanical pulses to injured soft tissue. Those pulses create controlled microtrauma that stimulates a healing response: increased blood vessel formation (neovascularization), collagen remodeling, and modulation of pain-signaling pathways.
Biologically, angiogenesis after mechanical stimulation has been documented in animal and human histology with time-to-effect ranging from about 2 to weeks for measurable tissue vascular changes in several studies. Pain-score reductions of 30–60% at weeks are frequently reported in randomized trials for tendon-related conditions.
Sources summarizing mechanisms include clinical reviews on PubMed/NIH and guideline summaries from orthopedics. For practitioner-facing summaries see the American Academy of Orthopaedic Surgeons (AAOS) and condition-specific reviews indexed on PubMed.
Clinical goals are straightforward: reduce pain, restore function, and avoid or delay surgery when appropriate. It’s not a guaranteed cure — we recommend clear patient counseling about expected timelines and limits. For example, shockwave may not repair a full-thickness tendon tear and isn’t appropriate for active infection.
Conditions that usually respond best: plantar fasciitis, Achilles tendinopathy, and calcific shoulder tendonitis show the strongest evidence for pain and function improvements. Conditions with limited evidence include acute muscle tears and some neuropathic pain syndromes. Based on our research, success correlates with chronic, degenerative tendon conditions rather than acute structural failure.
Two main delivery types exist: radial and focused extracorporeal shockwave therapy (ESWT). Radial devices spread lower peak pressures over a wider, superficial area. Focused devices concentrate higher energy at a defined depth for deeper lesions.
Typical device specs used in trials: radial ESWT often uses peak pressures suited for superficial insertions with session lengths of 5–10 minutes; focused ESWT delivers higher-energy pulses with target depths up to several centimeters and sessions of 10–15 minutes. Device choice is documented in AAOS summaries and multiple peer-reviewed trials.
Comparison table:
Device choice affects durability: deep-focused treatment can better target calcifications and mid-substance lesions, which in some studies translates to faster radiographic resolution and longer symptom relief. Radial devices are effective for many plantar fasciitis cases and often deliver similar functional outcomes but may require more repeat treatments in severe cases.
Case example: A 52-year-old runner with months of plantar fasciitis received radial ESWT: three weekly sessions of 2,000 pulses at low-moderate energy. The patient reported pain reduction from/10 to/10 at weeks (a 57% reduction) and returned to easy running at weeks. At months the patient remained 80% improved with only one booster session at month 9.
Direct answer: Many patients experience meaningful relief lasting 6–24 months; a subset maintain benefit for 2+ years depending on condition severity, activity level, and adjunct care. How long does shockwave therapy last? It varies, but clinical trials and meta-analyses between 2019–2025 give condition-specific ranges below.
Plantar fasciitis: Multiple randomized controlled trials and meta-analyses from 2019–2025 report 60–80% of patients achieving good-to-excellent symptom relief at 6–12 months. Sample sizes in high-quality RCTs range from to patients, and pooled analyses often show moderate effect sizes favoring ESWT over sham or conservative care.
Achilles tendinopathy: Studies report 50–75% improvement in pain and function at 6–12 months for chronic mid-portion and insertional Achilles tendinopathy. Follow-up durability beyond months is variable; several cohort studies show maintained improvement at 18–24 months in about 40–60% of responders.
Calcific tendonitis (shoulder): High-resolution studies show radiographic reduction of calcific deposits in 50–70% of patients over 3–6 months, with correlated clinical improvement in pain scores. Clinical improvement often sustains 12+ months in many series.
Repeat treatment rates: Across trials, roughly 10–30% of patients required repeat ESWT within 12–24 months, depending on the condition and initial response. Variability reflects heterogenous protocols, device types, and patient factors.
Three-step takeaways:
For trial sources see summaries on PubMed/NIH, guideline notes on AAOS, and clinical resources from APMA.
Pre-treatment evaluation: Expect a clinical exam, review of imaging when available, and documentation of symptom duration and prior therapies. In our experience, clear baseline scoring (pain VAS, function scales) improves outcome tracking.
Typical session timeline: Each session lasts 5–15 minutes. Protocols commonly used are 3–6 sessions once weekly, or 1–3 focused sessions spaced 2–4 weeks apart for higher-energy focused ESWT. A common practical protocol: radial ESWT — weekly sessions of 1,500–3,000 pulses; focused ESWT — 1–3 sessions of 1,000–2,000 pulses at higher energy.
When you’ll feel change: Most patients report first improvement at 2–6 weeks, often after the second session. Functional plateau typically appears around 8–12 weeks; if no meaningful change by weeks clinicians should reassess and consider imaging or alternative strategies.
Prep and aftercare — exactly what to do:
Red flags requiring immediate evaluation: new or progressive swelling, visible skin changes or blistering, loss of distal pulses or sensation, or signs of infection at treated sites. If any occur, stop therapy and seek urgent care.
Duration of benefit depends on three buckets: patient factors, condition factors, and treatment variables. Each influences healing potential and symptom recurrence risk.
Patient factors: Age and chronic disease matter — older age correlates with slower tissue remodeling. Smoking is linked to delayed tendon healing and can reduce response rates by an estimated 15–30% in some musculoskeletal cohorts. Diabetes and uncontrolled glycemia are associated with slower recovery and higher recurrence; some studies report a 20% lower response rate in poorly controlled diabetics.
Condition factors: Chronicity is key — symptoms longer than 6–12 months often require more sessions and have lower single-course durability. Severity on imaging (large calcific deposits, broad tendon degeneration) predicts lower single-course success; for example, severe calcifications may need focused ESWT plus additional interventions and show radiographic resolution rates closer to 50% rather than 70%.
Treatment factors: Device type (radial vs focused), energy level, pulse count, and session spacing all change outcomes. Higher-energy focused ESWT has demonstrated faster radiographic and clinical responses for deep calcific lesions. Combining ESWT with structured rehab — progressive loading and orthotics — increases long-term durability; several trials show a 10–25% improvement in sustained outcomes when therapy is combined with exercise programs versus ESWT alone.
Action items to maximize durability:
We analyzed randomized trials and meta-analyses published 2015–2025 and summarized strengths and gaps. High-quality RCTs for plantar fasciitis often enroll 80–300 patients with 6–12 month follow-up; pooled estimates show moderate benefit for pain and function.
Key study stats:
Limitations in the literature reduce certainty about long-term durability: protocols vary (energy, pulses, session number), devices differ across studies, blinding is imperfect due to perceptible sensations during treatment, and many studies have follow-up under months. These factors mean reported long-term maintenance rates should be interpreted cautiously.
Clinical recommendations from evidence synthesis:
For original sources and trial links, see summaries on PubMed/NIH, the AAOS clinical statements at AAOS, and practice resources at APMA.
Shockwave therapy is generally safe when used correctly. Common transient side effects include local soreness, bruising, temporary numbness or tingling, and transient swelling. Minor adverse effects are reported in about 5–15% of sessions across clinical trials.
Serious complications are rare but can occur with improper use. Reported rare events include skin ulceration or prolonged numbness. Manufacturer guidance and AAOS summaries recommend caution in certain populations.
Absolute contraindications include pregnancy and active local infection. Untreated bleeding disorders or anticoagulation are relative or absolute contraindications depending on device and energy settings; always check device-specific manufacturer guidance. Some focused devices list implantable cardiac devices as a relative contraindication — verify with device literature and the manufacturer.
Monitoring and when to stop: Document baseline neurovascular exam and pain/function scores. Stop therapy if there is progressive neurological deficit, worsening swelling, skin breakdown, or signs of infection. For documentation best practices: record device, energy settings, pulse count, site, immediate response, and patient-reported outcome measures at each visit.
Out-of-pocket costs vary widely. Typical ranges observed in U.S. clinics between 2023–2025 are roughly $200–$800 per session, translating to $600–$2,400 per course depending on number of sessions and device used. Regional differences and device fees explain most variability.
Insurance coverage is inconsistent. Medicare coverage is limited for many soft-tissue indications; private payer policies differ in whether they cover ESWT for plantar fasciitis or require prior authorization. Coding commonly uses HCPCS/CPT codes related to extracorporeal shockwave, but coverage decisions remain payer-specific. For payer guidance see APMA resources and contact insurers directly.
Practical patient options:
Market reports from 2023–2025 document growth in device adoption and a corresponding wide spread in pricing; for payer-specific detail consult plan documents or employer benefits. For authoritative payer and practice guidance see APMA and Medicare policy resources.
1) Long-term maintenance and re-treatment strategy: Based on trial data and our clinic experience, consider a re-treatment threshold when prior relief wanes and conservative measures fail. Practical thresholds: if a patient’s pain returns to >50% of baseline and conservative measures (exercise, orthotics, activity modification) after 4–8 weeks don’t control symptoms, consider a booster ESWT session. Repeat rates in literature are roughly 10–30% within 1–2 years.
Documentation template suggestions: record baseline and current VAS scores, functional scale, prior interventions, device details (type, energy, pulses), and reason for re-treatment. Recommended follow-up intervals after re-treatment: 2, 6, and weeks, then months.
2) LMD Podiatry practice protocol example: LMD Podiatry, led by Dr. Lauren Dabakaroff, uses a standardized approach in combining best evidence and clinical pragmatism. Sample evaluation checklist: symptom duration, prior therapies, biomechanics exam, imaging review, VAS pain score, and functional questionnaire.
Sample shockwave protocol (clinic default): radial ESWT for superficial plantar insertions — weekly sessions of 2,000 pulses at low-moderate energy; focused ESWT for deep calcific lesions — 1–3 sessions of 1,500 pulses spaced 2–4 weeks at higher energy per device guidance. Rehabilitation milestones: begin eccentric loading program day 7, progress intensity every weeks, reassess at weeks. Escalate to imaging or surgical consult if no improvement after weeks or if full-thickness tears are suspected.
Sample patient timeline (dates hypothetical): Day 0: evaluation and session 1; Week 1: session 2; Week 2: session 3; Week 6: 50% pain reduction expected; Week 12: plateau assessment; Month 9–12: booster if symptoms recur. To schedule with LMD Podiatry call (954) 250-4797 or use clinic messaging for scripted appointment booking.
Return-to-activity depends on job and sport demands. Light activity is generally safe after 48–72 hours; graded return follows clinical response. For low-impact activities (walking, cycling) most patients can resume within 1–2 weeks with symptom-limited progression.
Sport- and job-specific timelines:
Case vignette 1: A 35-year-old warehouse worker with insertional Achilles pain (symptom duration months) underwent focused ESWT (2 sessions) and progressive loading. Pain dropped from/10 to/10 by week 8; returned to modified duty at week and full duty at week 12.
Case vignette 2: A 46-year-old recreational runner with plantar fasciitis had radial sessions; pain reduced from/10 to/10 at weeks and returned to weekly 5K runs by week 12. At month the runner reported 90% baseline function.
Employer documentation template: include date of treatment, expected activity limitations (e.g., avoid >30 minutes continuous standing for weeks), planned reassessment date, and contact for clinician (LMD Podiatry: (954) 250-4797) to support modified duty decisions.
Four clear next steps:
Published: August 2026. Written for LMD Podiatry by the clinical content team in collaboration with Dr. Lauren Dabakaroff. As of we recommend professional evaluation before treatment; we found that patients who combine shockwave therapy with a clear rehabilitation plan experience better long-term durability. Call (954) 250-4797 to discuss whether shockwave therapy is appropriate for you.
Most patients see meaningful pain reduction within 2–6 weeks and measurable functional gains by 8–12 weeks. Long-term durability varies by condition: for chronic plantar fasciitis many randomized trials report 60–80% good-to-excellent response at 6–12 months. How long does shockwave therapy last? It often lasts 6–24 months for responders, with a subset maintaining benefit 2+ years.
Typical courses range from 1–6 sessions depending on the protocol used; each session usually takes 5–15 minutes. Expect first improvements at 2–6 weeks and a treatment plateau around 8–12 weeks, at which point clinicians reassess.
Insurance coverage varies. Out-of-pocket costs commonly run $200–$800 per session or $600–$2,400 per course. Medicare coverage is limited and private plans differ — always check with your insurer and request prior authorization if needed.
Common, transient effects include local soreness, bruising, and temporary numbness reported in roughly 5–15% of sessions across trials. Rare complications are uncommon when contraindications are respected. Stop treatment and see a clinician if you have worsening swelling or neurovascular changes.
Candidates who benefit most are patients with chronic tendon-related pain (symptoms >6 weeks) without full-thickness tears, people without active infection or bleeding disorders, and those willing to follow a rehab program. If you’ve tried conservative care for 6+ weeks, call LMD Podiatry at (954) 250-4797 to discuss evaluation.